Targeting Cystic Fibrosis Using a Novel Inhalation Therapy - $421,545

Currently treatments for cystic fibrosis infection are via oral, intravenous or lengthy inhalation processes. This can lead to significant side effects, consequent poor patient compliance, and limited therapeutic efficacy. We will develop and test a novel high-dose inhalation dry power device containing an antibiotics for the rapid treatment of infection in cystic fibrosis therapy.